Buprenorphine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00921 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 52 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acute intermittent porphyria | KG + DL |
| 2 | lingual-facial-buccal dyskinesia | KG + DL |
| 3 | chronic tic disorder | KG + DL |
| 4 | continuous spikes and waves during sleep | KG + DL |
| 5 | benign shuddering attacks | KG + DL |
| 6 | extrapyramidal and movement disease | KG + DL |
| 7 | schizophreniform disorder | KG + DL |
| 8 | schizophrenia | KG + DL |
| 9 | benign paroxysmal tonic upgaze of childhood with ataxia | KG + DL |
| 10 | psychogenic movement disorders | KG + DL |
| 11 | primary orthostatic tremor | KG + DL |
| 12 | tremor-nystagmus-duodenal ulcer syndrome | KG + DL |
| 13 | drug-induced dyskinesia | KG + DL |
| 14 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 15 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 16 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 17 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 18 | hydranencephaly (disease) | KG + DL |
| 19 | myopia 26, X-linked, female-limited | KG + DL |
| 20 | atypical glycine encephalopathy | KG + DL |
| 21 | syndromic myopia | KG + DL |
| 22 | lissencephaly with cerebellar hypoplasia | KG + DL |
| 23 | myopia X-linked | KG + DL |
| 24 | mental disorder | KG + DL |
| 25 | impulse control disorder | KG + DL |
| 26 | intermittent explosive disorder | KG + DL |
| 27 | schizoaffective disorder | KG + DL |
| 28 | substance withdrawal syndrome | KG + DL |
| 29 | skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome | KG + DL |
| 30 | postpartum psychosis | KG + DL |
| 31 | psychotic disorder | KG + DL |
| 32 | substance-induced psychosis | KG + DL |
| 33 | tic disorder | KG + DL |
| 34 | porphyria | KG + DL |
| 35 | manic bipolar affective disorder | KG + DL |
| 36 | progressive encephalopathy with leukodystrophy due to DECR deficiency | KG + DL |
| 37 | neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive | KG + DL |
| 38 | treatment-refractory schizophrenia | KG + DL |
| 39 | alcoholic psychosis | KG + DL |
| 40 | early-onset schizophrenia | KG + DL |
| 41 | drug/alcohol-induced mental disorder | KG + DL |
| 42 | hyperekplexia | KG + DL |
| 43 | oppositional defiant disorder (disease) | KG + DL |
| 44 | diaphanospondylodysostosis | KG + DL |
| 45 | psychosexual disorder | KG + DL |
| 46 | REM sleep behavior disorder | KG + DL |
| 47 | parkinsonian disorder | KG + DL |
| 48 | communication disorder | KG + DL |
| 49 | dissociative disorder | KG + DL |
| 50 | fetal nicotine spectrum disorder | KG + DL |
(Showing top 50 of 52 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.